Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes November 29, 2018 • 7:00 AM EST
Tonix Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights November 9, 2018 • 7:30 AM EST
Tonix Pharmaceuticals Announces New Patent Coverage Protecting Tonmya® November 7, 2018 • 7:00 AM EST
Tonix Pharmaceuticals Presented Results and Retrospective Analyses of Phase 3 P301 “HONOR” Study in Poster Presentation at CNS Summit 2018 November 6, 2018 • 7:00 AM EST
Tonix Pharmaceuticals to Present at BIO-Europe International Partnering Conference November 1, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals Announces Innovative Design in Next Phase 3 Study of Tonmya® for PTSD, Following FDA Meeting October 31, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in Poster Presentations at CNS Summit 2018 October 29, 2018 • 7:00 AM EDT
Tonix Pharmaceuticals to Present at the Dawson James Securities Small Cap Growth Conference October 23, 2018 • 7:00 AM EDT
